Colorado Sued by Amgen Over PDAB Price Cap on Enbrel

November 13, 2025

EGWP marketplace medicaid Medicare

Amgen, the manufacturer of Enbrel (a rheumatoid arthritis and ankylosing spondylitis treatment), filed a lawsuit against the Colorado Prescription Drug Affordability Review Board (PDAB) after the board determined Enbrel to be “unaffordable” and established an upper payment limit (UPL) of $600 per 50mg unit of the drug. In the suit, Amgen claims the UPL, which imposes price caps on the sale or purchase of Enbrel beginning Jan. 1, 2027, is unconstitutional and jeopardizes patient access to the drug.

Amgen previously sued the PDAB when the board was first considering a UPL, but the lawsuit was dismissed by a federal judge on the grounds that the company had not demonstrated it would likely suffer harm from the Board’s actions. The case is scheduled for a preliminary hearing in Jan. 2026. Colorado is the first state to set a UPL through a PDAB.

Initiatives

Calls grow for Drug Patent reform

In a recent blog post, the Pharmaceutical Care Management Association (PCMA) highlighted increased attention to pharmaceutical companies’ abuse of drug patents. Last month, the Supreme Court unanimously ruled in favor of a generic drugmaker in a “skinny labeling” case, a victory for patients. Skinny labels allow generic and biosimilar competitors to launch products for non-patented indications, helping accelerate […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

perspectives

AHIP calls for Bipartisan reform to address health care cost drivers

On July 23, AHIP President and CEO Mike Tuffin wrote an opinion piece in The New York Times saying, “common-sense bipartisan reforms are needed to promote competition in care delivery and prescription drugs, protect consumers from providers and drugmakers’ anticompetitive practices and transition away from the perverse incentives of fee-for-service medicine.” Tuffin notes that health […]
read more >

August 11, 2026

EGWP marketplace medicaid Medicare

Solutions

PCMA urges preserving patient access and flexibility in new fertility benefits rule

PCMA recently submitted comments to HHS, DOL, and the Treasury (the Departments) in response to the proposed rule establishing a new category of limited excepted benefits for fertility services. PCMA supports the Departments’ goal of expanding access to fertility care while encouraging employer innovation but urged several targeted refinements to ensure the framework is operationally […]
read more >

August 11, 2026

marketplace medicaid

You may also like